Page 67 - 84_04
P. 67
20. Abedalthagafi M, Barakeh D, Foshay KM. Lisardo Boscá Gomar
Immunogenetics of glioblastoma: the future of
personalized patient management. NPJ Precis Oncol Cancer Cell 2018; 34: 186-95.
2018; 2: 27. 10.1038/s41698-018-0070-1 10.1016/j.ccell.2018.04.011
22. Verma V. Economic sustainability of immune-
21. Waitkus MS, Diplas BH, Yan H. Biological Role and checkpoint inhibitors: the looming threat. Nat Rev
Therapeutic Potential of IDH Mutations in Cancer. Clin Oncol 2018; 15: 721-2. 10.1038/s41571-018-
0086-z
394 @Real Academia Nacional de Farmacia. Spain
